Medicxi launches Alys Pharmaceuticals with $100m funding to develop groundbreaking therapies in immunodermatology. The company aims to address unmet needs ...
Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...